Not finding it? Sign in to also search OpenAlex live.
-
Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans2020 Translational Psychiatry article Neuroscience Neurotransmitter Receptor Influence on Behavior Open access cited by 2 patents
Giacomo Salvadore, Pascal Bonaventure, Anantha Shekhar, Philip L. Johnson, Brian Lord, Brock T. Shireman, +14 more
51citations -
Orexin-A measurement in narcolepsy: A stability study and a comparison of LC-MS/MS and immunoassays2021 Clinical Biochemistry article Neuroscience Sleep and Wakefulness Research Open access cited by 2 patents
Mikael Lindström, Mink Sebastian Schinkelshoek, Pentti J. Tienari, Jyrki P. Kukkonen, Risto Renkonen, Rolf Fronczek, +2 more
20citations -
Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 12025 New England Journal of Medicine article Neuroscience Sleep and Wakefulness Research Open access
Yves A Dauvilliers, Giuseppe Plazzi, Emmanuel Mignot, Gert Jan Lammers, Rafael del Río Villegas, Ramin Khatami, +13 more
62citations -
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects
Benjamin Berger, Sander Brooks, Rob G. J. A. Zuiker, Muriel Richard, Clemens Muehlan, Jasper Dingemanse
21citations -
Efficacy and Safety of TAK-861, an Oral Orexin Receptor 2 Agonist, in Individuals with Narcolepsy Type 1: Results from a Phase 2 Trial and Long-Term Extension Study Interim Analysis (P12-4.002)
Yves A Dauvilliers, Emmanuel Mignot, Giuseppe Plazzi, Gert Jan Lammers, Harisha Kadali, Ellie Stukalin, +6 more
1citations -
Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial
Giuseppe Plazzi, Ronald R. Grunstein, Emmanuel Mignot, Gert Jan Lammers, David Thomas Plante, Erik Buntinx, +8 more
0citations -
Improvement in Patient-reported Disease Severity, Cognitive Functioning, and Fatigue in Patients With Narcolepsy Type One Treated With Alixorexton, an Orexin Two Receptor Agonist, in the Vibrance-1 Phase Two Study (P6-14.002)
Yves A Dauvilliers, Ronald Grunstein, Emmanuel Mignot, Gerrit Lammers, David Plante, Erik Buntinx, +7 more
0citations -
Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator2022 Clinical Pharmacology & Therapeutics article Psychology Sleep and Work-Related Fatigue Open access
Clemens Muehlan, Sander Brooks, Cédric Vaillant, Michael Meinel, Gabriël E. Jacobs, Rob G. J. A. Zuiker, +1 more
36citations